23andMe announces layoffs totaling 40% of workforce, discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe Cuts 40% of Its Workforce and Discontinues Therapeutics Division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe lays off 40% of its workforce, ends therapeutics division
Me is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival. The once-popular DNA-testing site will also halt work on therapies it was developing.
What 23andMe business troubles could mean for millions of users' genetic data
No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...
NBC Los Angeles2d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
Hosted on MSN1d
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly ... The company announced two weeks ago that it had ...
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...
23andMe appoints three former CFOs as new directors—after the previous board all resigned
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Rolling Out1d
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...
11Alive1d
23andMe announces layoffs, will cut 40% of workforce
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed ...
Benzinga.com1d
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...